59433-50-0

Basic information

• Product Name: BOC-DL-PRO-OH
• Synonyms: PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;BOC-DL-PROLINE;BOC-DL-PRO-OH;1-(TERT-BUTOXYCARBONYL)PYRROLIDINE-2-CARBOXYLIC ACID;AKOS 91525;N-BOC-DL-PROLINE;REF DUPL: Boc-DL-Pro-OH;1-(tert-butoxycarbonyl)proline [Boc-DL-Pro-OH]
• CAS NO: 59433-50-0
• Molecular Formula: C10H17NO4
• Molecular Weight: 215.25
• Product Categories: Boc-Amino Acids and Derivative;Boc-Amino acid series;Boc Amino Acids
• Mol File: 59433-50-0.mol
• Article Data: 197

Chemical Properties

• Melting Point: 133-135°C
• Boiling Point: 337.2 °C at 760 mmHg
• Flash Point: 157.7 °C
• Appearance: /
• Density: 1.201 g/cm³
• Storage Temp.: 2-8°C
• PKA: 4.01±0.20(Predicted)
• CAS DataBase Reference: BOC-DL-PRO-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-DL-PRO-OH(59433-50-0)
• EPA Substance Registry System: BOC-DL-PRO-OH(59433-50-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 59433-50-0(Hazardous Substances Data)

Usage

Uses

(±)-N-(tert-Butoxycarbonyl)proline is a useful reagent for the enantiospecific preparation of functionalized hindered triazolopyridinones.

Upstream product

• 13303-10-1 tert-Butyl 4-nitrophenyl carbonate 
• 147-85-3 L-proline 
• 75-44-5 phosgene 
• 1907-33-1 lithium tert-butoxide 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 98015-52-2 1,2,2,2-Tetrachloroethyl tert-Butyl Carbonate 
• 50739-44-1 1-(t-butoxycarbonyl)-1,2,4-triazolo<4,3-a>pyridinium-3-olate 
• 81616-10-6 tert-butyl α-methoxyvinyl carbonate 
• 104272-92-6 2-t-butoxycarbonyloxy-3,6-diisopropylpyrazine 
• 104272-95-9 t-butyl S-3,6-diisopropylpyrazin-2-ylthiolcarbonate 
• 75844-68-7 tert-butyl 2-oxo-1,3-oxazole-3(2H)-carboxylate 
• 89985-91-1 tert-butyl pyridin-2-yl carbonate 

Downstream Products

• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 81771-37-1 Gly-Pro-Hyp-Gly-Ala-Gly 
• 24050-88-2 Boc-Pro-Phe-OPic 
• 60482-97-5 NT_10-13 
• 52071-65-5 N-tert-butyloxycarbonyl-L-prolyl-L-phenylalanine 
• 69038-47-7 Boc-L-Pro-L-Leu-OBzl 
• 95755-29-6 Boc-Pro-Δ-Leu-OMe 
• 110579-78-7 N-tert-butyloxycarbonyl-L-prolyl-L-methionine p-nitrophenyl ester 
• 101692-93-7 H-Pro-Val-OBzl 
• 132149-56-5 N-t-butyloxycarbonylprolyl-p-nitrophenylalanine 
• 125405-89-2 (S)-2-({[(S)-1-(Benzyloxycarbonylmethyl-carbamoyl)-ethylcarbamoyl]-methyl}-carbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 86645-64-9 iBuOCO-Lys(Z)-OMe 
• 112839-80-2 N^α--N^γ-(benzyloxycarbonyl)-L-lysine 
• 128120-96-7 N-t-Boc-proline-isoleucine phenacyl ester 

Relevant articles and documents

Formal Fluorinative Ring Opening of 2-Benzoylpyrrolidines Utilizing [1,2]-Phospha-Brook Rearrangement for Synthesis of 2-Aryl-3-fluoropiperidines

A ring expansion of 2-benzoylpyrrolidines, which involves the formal fluorinative ring opening utilizing the [1,2]-phospha-Brook rearrangement under Br?nsted base catalysis and a subsequent intramolecular reductive amination, was developed. The operationally simple three-step protocol provides an efficient access to 2-aryl-3-fluoropiperidines. The methodology was further applied to the syntheses of azepanes and tetrahydroquinolines.

Leonurine derivative and application thereof in preparing medicine for preventing or treating ischemic cerebrovascular diseases

The invention provides a leonurine derivative and application of the leonurine derivative in preparation of a medicine for preventing or treating ischemic cerebrovascular diseases. The leonurine derivative has a structure as shown in a general formula (I), wherein X is selected from O or NH; Y is selected from any one of natural amino acid, substituted amino acid or amino alcohol; Z is selected from H, proline and any substituted proline. Pharmacological experiments prove that the leonurine derivative provided by the invention has the effects of neuroprotection, cerebral infarction area reduction and animal neurobehavioral scoring, and is good in safety, so that the leonurine derivative has important significance for developing novel medicines for preventing or treating ischemic cerebrovascular diseases.

STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided. (I)